Abstract:INTRODUCTION AND OBJECTIVES: AKR1C3, as a crucial steroidogenic enzyme, facilitated intratumoral androgen biosynthesis and androgen receptor (AR) reactivation in the development of castration-resistant prostate cancer. Also, amount of data have shown that AKR1C3 expression was significantly elevated in clinical metastatic prostate cancer (PCa) specimens, indicating an alternative role of AKR1C3 in PCa metastasis. Epithelial-mesenchymal transition (EMT) has been recognized to play pivotal roles in promoting carcinoma invasion and metastasis; however, the roles of AKR1C3 in EMT and PCa metastasis have not been fully elucidated. METHODS: C4-2, 22RV1-T and PC-3 cells with higher AKR1C3 expression were selected and treated with several specific AKR1C3 shRNAs or small molecule inhibitor, and the cell migration and invasion abilities were detected by wound healing assay and Transwell assay. The expression of EMT markers (i.e., E-cadherin and vimentin) and the related transcription factors (i.e., Snail, Slug, ZEB1 and Twist1) was examined by Western blot or quantitative PCR assays, and the phosphorylation of AKT or ERK was detected by Western blot. Also, the expression of vimentin, ZEB1 and p-ERK (T202/Y204) was detected by immunohistochemical staining in PC-3 xenograft tissues after AKR1C3 inhibitor treatment. The correlation between AKR1C3 and EMT markers (including EMT-related transcription factors) expression in clinical specimens from tissue microarray or TCGA database was analyzed. RESULTS: AKR1C3 was overexpressed in more aggressive PCa cell lines regardless of the AR status. Knock-down of AKR1C3 expression or inhibition of AKR1C3 activity could significantly suppressed cell migration and invasion abilities in vitro. Also, knock-down of AKR1C3 expression or inhibition of AKR1C3 activity could increase E-cadherin expression but decrease vimentin expression, in which the phosphorylation of ERK and the transcription factor ZEB1 expression were specifically downregulated. In consistency, inhibition of AKR1C3 activity by inhibitor treatment could decrease the expression of vimentin, ZEB1 and p-ERK (T202/Y204) in xenograft tissues in vivo. Moreover, there was a significant correlation between AKR1C3 and EMT markers (i.e., E-cadherin, vimentin and ZEB1) in human PCa specimens. CONCLUSIONS: AKR1C3 is a novel EMT regulator in PCa metastasis through activation of MAPK/ERK signaling and upregulation of ZEB1 expression.

Data from MAP3K7-IKK Inflammatory Signaling Modulates AR Protein Degradation and Prostate Cancer Progression

ANKRD22 is Involved in the Progression of Prostate Cancer

Inactivation of AR/TMPRSS2-ERG/Wnt Signaling Networks Attenuates the Aggressive Behavior of Prostate Cancer Cells

Scaffold protein MAPK8IP2 expression is a robust prognostic factor in prostate cancer associated with AR signaling activity

ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression

AR loss in prostate cancer stroma mediated by NF-κB and p38-MAPK signaling disrupts stromal morphogen production

P21-Activated Kinase 6 (PAK6) Inhibits Prostate Cancer Growth Via Phosphorylation of Androgen Receptor and Tumorigenic E3 Ligase Murine Double Minute-2 (Mdm2)*

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

Data from Suppression of Tak1 Promotes Prostate Tumorigenesis

Data from Infiltrating Macrophages Promote Prostate Tumorigenesis Via Modulating Androgen Receptor-Mediated CCL4–STAT3 Signaling

MAP3K7 Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of CHD1

MAPK4 Promotes Prostate Cancer by Concerted Activation of Androgen Receptor and AKT.

Effect of MAP3K8 on Prognosis and Tumor-Related Inflammation in Renal Clear Cell Carcinoma

MP62-19 AKR1C3 OVEREXPRESSION IN PROSTATE CANCER PROMOTES EPITHELIAL-MESENCHYMAL TRANSITION AND METASTASIS VIA ACTIVATION OF MAPK/ERK SIGNALING AND UPREGULATION OF ZEB1

Compensatory Upregulation Of Tyrosine Kinase Etk/Bmx In Response To Androgen Deprivation Promotes Castration-Resistant Growth Of Prostate Cancer Cells

CD147 modulates androgen receptor activity through the Akt/Gsk-3 beta/beta-catenin/AR pathway in prostate cancer cells

MAPK8IP2 is a Potential Prognostic Biomarker and Promote Tumor Progression in Prostate Cancer

Deregulated PP1α Phosphatase Activity Towards MAPK Activation is Antagonized by a Tumor Suppressive Failsafe Mechanism

CAMK2N1 Inhibits Prostate Cancer Progression Through Androgen Receptor-Dependent Signaling

Data from <i>Pten</i> Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells

AR-negative prostate cancer is vulnerable to loss of JMJD1C demethylase